Table 1 Clinical characteristics of patients treated with carbapenem vs. cefepime/piperacillin-tazobactam
Carbapenem (n = 22) | P-T/CEF (n = 55) | P | |
|---|---|---|---|
Age, years (IQR) | 71 (51–77) | 76 (65–82) | 0.053 |
Sex, male, n (%) | 16 (73) | 41 (75) | 0.999 |
Comorbidities, n (%) | |||
- Ischemic heart disease - Heart failure - Dementia - COPD - Diabetes mellitus - Chronic kidney failure - Solid tumour | 2 (9) 2 (9) 2 (9) 2 (9) 4 (18) 3 (14) 6 (27) | 9 (16) 4 (7) 6 (11) 7 (13) 8 (15) 6 (11) 17 (31) | 0.497 0.999 0.999 0.712 0.734 0.709 0.999 |
Charlson index ≥ 3, n (%) | 8 (36) | 24 (44) | 0.616 |
Acquisition type, n (%) | |||
- nosocomial - community - healthcare | 11 (50) 10 (46) 1 (5) | 30 (55) 20 (36) 5 (9) | 0.803 0.606 0.668 |
Source of infection, n (%) | |||
- urinary - catheter - respiratory - abdominal - surgical wound - cutaneous - unknown | 8 (36) 4 (18) 0 3 (14) 0 1 (5) 1 (5) | 18 (33) 7 (13) 2 (4) 5 (9) 4 (7) 0 3(6) | 0.794 0.719 0.999 0.682 0.320 0.286 0.999 |
Previous procedures, n (%) | |||
- surgery previous month - urinary catheter - vascular catheter | 7 (32) 10 (46) 7 (32) | 17 (31) 15 (27) 9 (16) | 0.999 0.178 0.212 |
Sepsis, n (%) | 13 (59) | 21 (38) | 0.129 |
ICU, admission, n (%) | 7 (32) | 9 (16) | 0.212 |
Time until adequate treatment, mean days (IQR) | 1 (1–3) | 2 (1–2) | 0.907 |
Treatment duration, mean days (IQR) | |||
- Intravenous days - Oral days - Total duration | 10 (7–11) 0 (0) 11 (8–17) | 9 (6–13) 3 (0–7) 12 (9–15) | 0.383 0.020 0.390 |
OST, n (%) | 4 (18) | 32 (58) | 0.002 |
In-hospital stay, mean days (IQR) | 17 (10–41) | 16 (10–22) | 0.363 |
Adverse events, n (%) | 1 (5) | 1 (2) | 0.492 |
Evolution, n (%) | |||
- Clinical cure - Recurrence - 14-day mortality | 18 (82) 2 (9) 4 (18) | 50 (91) 1 (2) 3 (6) | 0.267 0.195 0.098 |
Clinical success | 17 (77) | 50 (91) | 0.138 |